Transgenerational Exposure to Environmental Tobacco Smoke

Xavier Joya 1, Cristina Manzano 2, Airam-Tenesor Álvarez 2, Maria Mercadal 2, Francesc Torres 2, Judith Salat-Batlle 1 and Oscar Garcia-Algar 1,2,*

1 Unitat de Recerca Infància i Entorn (URIE), Institut Hospital del Mar d’Investigacions Mèdiques (IMIM), Barcelona 08003, Spain; E-Mails: jjoya@imim.es (X.J.); jsalat@imim.es (J.S.-B.)

2 Paediatric Unit, Hospital del Mar, Barcelona 08003, Spain; E-Mails: 61059@parcdesalutmar.cat (C.M.); 60809@parcdesalutmar.cat (A.-T.A.); 60810@parcdesalutmar.cat (M.M.); 61041@parcdesalutmar.cat (F.T.)

* Author to whom correspondence should be addressed; E-Mail: 90458@hospitaldelmar.cat; Tel.: +34-932-483-551; Fax: +34-932-483-254.

Received: 30 May 2014; in revised form: 7 July 2014 / Accepted: 8 July 2014 / Published: 16 July 2014

Abstract: Traditionally, nicotine from second hand smoke (SHS), active or passive, has been considered the most prevalent substance of abuse used during pregnancy in industrialized countries. Exposure to environmental tobacco smoke (ETS) is associated with a variety of health effects, including lung cancer and cardiovascular diseases. Tobacco is also a major burden to people who do not smoke. As developing individuals, newborns and children are particularly vulnerable to the negative effects of SHS. In particular, prenatal ETS has adverse consequences during the entire childhood causing an increased risk of abortion, low birth weight, prematurity and/or nicotine withdrawal syndrome. Over the last years, a decreasing trend in smoking habits during pregnancy has occurred, along with the implementation of laws requiring smoke free public and working places. The decrease in the incidence of prenatal tobacco exposure has usually been assessed using maternal questionnaires. In order to diminish bias in self-reporting, objective biomarkers have been developed to evaluate this exposure. The measurement of nicotine and its main metabolite, cotinine, in non-conventional matrices such as cord blood, breast milk, hair or meconium can be used as a non-invasive measurement of prenatal SMS in newborns. The aim of this review is to highlight the prevalence of ETS (prenatal and postnatal) using biomarkers in non-conventional matrices before and after the implementation of smoke free policies and health effects related to this exposure during foetal and/or postnatal life.
Keywords: environmental tobacco smoke; non-conventional matrices; nicotine; cord blood; free-smoke policies; newborn; children

1. Introduction

Second-hand tobacco smoke (SHS) consists of exhaled smoke as well as side-stream smoke that is released from the burning cigarette between inhalations and it has a very similar composition [1]. SHS is referred to as “environmental” tobacco smoke (ETS) [2]. The composition of SHS changes as it becomes diluted with ambient air, with its distribution in the environment and as it interacts over time with compounds found in the environment. However, no matter how SHS changes in the environment, it still contains significant levels of nicotine (NIC). NIC concentrations in the air in homes of smokers range on average from 2–10 μg/m$^3$ [2].

Tobacco is also a major burden on people who do not smoke. As developing individuals, children are particularly vulnerable to the negative effects of SHS, which may even occur before birth [3–5]. Furthermore, they are unable to influence their own degree of exposure. ETS, side-stream, or SHS are associated with significant health risks such as cancer, heart disease, asthma, and/or respiratory illnesses. In the field of perinatal epidemiology, children’s exposure to tobacco constituents during foetal development through the placenta, when the environment is inside the uterus, and via exposure during childhood is perhaps the most ubiquitous and hazardous of children’s environmental exposures [6].

2. Materials and Methods

The following eligibility criteria were used: (a) clinical studies; (b) laboratory-based investigations; (c) studies published only in English language letters to the Editor, historic reviews, commentaries and case-reports were excluded.

PubMed/MedLine (National Library of Medicine, Washington, DC, USA) databases were searched from 1988 up to and including June 2014 using different combinations of the following key words: “environmental tobacco smoke”, “passive”, “nicotine”, “secondhand” and “smoking”. Titles and abstracts of studies identified using the above-described protocol were screened by the authors and checked for agreement. Full-texts of studies judged by title and abstract to be relevant were read and independently evaluated by the authors with reference to the inclusion and exclusion criteria. Reference lists of articles retrieved from the initial search were hand-searched to identify any studies that could have remained unidentified in the previous step.

3. ETS and Health Effects in Neonatal and Paediatric Population: An Overview

Prenatal SHS exposure puts unborn babies at risk for (1) stillbirth and preterm delivery [7]; (2) growth retardation [7,8]; (3) congenital anomalies [8,9]; and (4) respiratory infections and asthma in childhood [4]. Worldwide, at least 40% of children are regularly exposed to SHS after birth, additionally predisposing them to upper and lower respiratory infections as well as asthma [10].

A meta-analysis on passive smoking during pregnancy and foetal health estimated that exposure of non-smoking pregnant women to SHS reduces mean birth weight by 33 g or more, and increases
the risk of a birth weight below 2500 g [5,11]. Similar to this study, many others reported a significant association between SHS and premature birth [12–16].

In addition, there is documented and unequivocal epidemiological evidence to support an association between active smoking during pregnancy and low birth weight (LBW) and growth retardation [17]. On the whole, data from several studies show that there is a dose-response effect of smoking on both mean birth weight and the incidence of LBW infants with an adjusted OR of 2.3 (95% CI 2.0–2.04) for smoking pregnant women compared to non-smokers [18,19]. A recent meta-analysis of 16 studies reported an OR for LBW of 1.22 (95% CI 1.10–1.35) [20].

Newborns of women who smoke have increased risks of congenital anomalies such as orofacial clefts [21]. A recent meta-analysis of 12 studies reported an association between ETS and an increased risk of having an infant with a congenital anomaly (OR 1.17; 95% CI 1.03–1.34) [8].

Active maternal smoking during pregnancy has been associated with a higher risk of behavioural disorders in children; a few cohort studies have studied its specific effects on the cognitive abilities of pre-schoolers by measuring smoking data prospectively. The disorders range from personality temperment to neuropsychiatric outcomes such as attention disorders (e.g., attention deficit hyperactivity disorder (ADHD)) [22]. Maternal smoking habits were associated with lowered cognitive development of children at age 4 years [23]. ETS is also associated with an increased risk of psychiatric morbidity. A recent meta-analysis found that NIC studies indicated a greater risk of ADHD-related disorders among children whose mothers smoked during pregnancy more than 10 cigarettes/day (OR 1.85 (95% CI 1.74–1.96); N = 175.869) [24].

Finally, the most studied health effect of ETS during prenatal and postnatal life has been the altered respiratory function. It is well known that prenatal maternal smoking and postnatal ETS lead to a dose-dependent increase in respiratory morbidity in infants and children. Exposure to ETS causes asthma, wheezing, cough, bronchitis, pneumonia, and impaired pulmonary function [25]. Several studies have shown a reduced lung function in newborns exposed passively to tobacco smoke during pregnancy [26–29]. Similarly, many studies demonstrated that parental smoking status has an important impact on asthma and wheezing illnesses in infants and children. A study conducted in 3-year-old children who were exposed both prenatally and postnatally to ETS reported increased prevalence of wheezing (OR, 1.14) when compared with children born to non-smoking parents [30]. Also, the incidence of lower respiratory illness (LRI) increases with parental smoking [31–34]. Long-term exposure to ETS creates a state of permanent inflammation and an imbalance in the lipid profile that leads to lipid accumulation in the blood vessels of the heart and aorta [35]. Children with long-term exposure to ETS may have an elevated risk for the development of premature coronary artery disease [36]. Hypertension is the leading risk factor for cardiovascular disease. Newborn infants of smoking parents show symptoms of cardiovascular stress hyperactivity. Simonetti et al. [37] found that both systolic (+1.0 mmHg) and diastolic (+0.5 mmHg) blood pressure were higher in children of smoking parents. In healthy preschool children, parental smoking is an independent risk factor for higher blood pressure, adding to other familial and environmental risk factors.
4. Biological Matrices to Evaluate ETS Prevalence in Paediatric Population

Prenatal tobacco exposure has been usually assessed using a self-reported maternal questionnaire [38–40]. However, difficulties in recognizing smoking behaviour or recalling smoking exposure, or changes in smoking habits during gestation could bias these assessments. In Mediterranean countries, with a high prevalence of young female smokers [41,42], questionnaires could be even less valid [43,44]. In addition, pregnant women, conscious of the risks of tobacco smoke for the foetus, may be reluctant to admit active (or passive) tobacco smoke exposure due to social pressure, guilt, or embarrassment [42,45].

Similar to other drugs of abuse, licit or illicit, biological markers specific to tobacco smoke have been identified in the past two decades to prevent reporting bias. NIC and its major metabolite, cotinine (COT), have been used as biomarkers for SHS in conventional (blood and urine) [46,47] and non-conventional matrices (saliva, meconium, and hair) [48–50] (Table 1).

Table 1. Biological matrices for the evaluation of prenatal and postnatal exposure to environmental tobacco smoke.

| Biological Matrix | Detection Window       | Collection               | Biomarker Levels for the Different Exposure Groups |
|-------------------|------------------------|--------------------------|---------------------------------------------------|
| **Prenatal evaluation**                          |                        |                          |                                                   |
| Maternal hair     | Months                 | Easy and non-invasive.   | Hair NIC is more precise that urine COT. NIC (ng/mg) |
|                   |                        | Hair washing to remove external contamination | of non-exposed: 0.53; highly exposed and smokers: 5.95 [48,51] |
| Cord serum        | Hours to days          | Easy and non-invasive   | COT levels in cord serum indicate fetal exposure to tobacco. COT (ng/mL) of no-exposure: <LOD; low-exposure: 1–14; medium-high exposure: >14 [52] |
|                   |                        | (at birth)              |                                                   |
| Neonatal urine    | 1 to 3 days before delivery | Easy and non-invasive | Close correlation between NIC and COT maternal and neonatal concentrations. COT (ng/mL) of non-exposed: 1.9 [53]; and exposed: 170.5 [54] |
| Amniotic fluid    | Months (1st and 2nd trimesters) | Invasive collection procedure | Human fetus exposed to higher NIC concentrations than the smoking mother [55] |
| Neonatal meconium | 2nd and 3rd trimesters of pregnancy | Easy and non-invasive. May be delayed until 3 days | Mean COT (ng/g) levels from: non-exposed to ETS: 6.0 [56] and highly exposed: 42.6 [56] |
| **Postnatal evaluation**                          |                        |                          |                                                   |
| Oral Fluid        | 0.5–36 h               | Easy and non-invasive.   | Salivary COT is more sensitive than NIC. COT (ng/mL) of non-exposed: 0.44; exposed: 3.38 [57] |
|                   |                        | Performed under direct observation |                                                   |
| Hair              | Months                 | Easy and non-invasive.   | Hair NIC is more precise that urine COT. NIC (ng/mg) of non-exposed: 0.53; highly exposed: 5.95 [51] |
|                   |                        | Hair washing to remove external contamination |                                                   |
| Teeth             | Years                  | Requires pulverization and organic washing. | NIC indicates cumulative exposure to tobacco smoke. |
|                   |                        |                          |                                                   |

NIC is the primary addictive component of tobacco and it is the major constituent of cigarettes. NIC presents a half-life of approximately 2–3 h in blood, followed by urinary excretion [60]. About 80% of
NIC is transformed to COT [61]. COT presents a longer biological half-life in comparison to NIC and it has been found to be directly related to daily cigarette consumption [62]. The measurement of COT in blood, saliva, or urine, has been used to support epidemiologic findings of causal relationships with SHS exposure [63].

4.1. Biological Matrices for the Evaluation of Prenatal Exposure to Environmental Tobacco Smoke

The concentrations in foetal blood can be indicative of transplacental passage of NIC and its metabolites during pregnancy. Concentrations of NIC metabolites in cord blood are in the order of ng/mL (the concentrations are two or three orders of magnitude lower than those detected in the amniotic fluid) [55]. Different cut-offs (14 and 21.5 ng/mL) have been proposed to differentiate between passive and active smokers. To differentiate between exposure and non-exposure to ETS, a cut-off value of 1 ng/mL has been proposed [40,52,64]. Garcia-Algar et al. [42,45] investigated the association between COT in cord serum and in maternal and newborn urine samples. Cord serum COT appeared to be the most sensitive biomarker for foetal exposure to smoking at the end of pregnancy, distinguishing not only active smoking from passive smoking, but also exposure to ETS from non-exposure.

Traditionally, urine has been considered the specimen of choice for neonatal drug testing for several reasons: even though urine collection is difficult, it is superior to the invasive serum collection and COT analysis in neonatal urine is an easy, rapid, and low-cost test [53]. Köhler et al. determined NIC, COT and trans-3′-hydroxicotinine in maternal and neonatal urine. A close correlation (which did not depend significantly on the time of urine collection) was found between maternal and neonatal NIC and COT concentrations [54]. A disadvantage of urine is that the time window of detection is short, reflecting drug use only a few days before delivery. Analysis of the neonatal urine may produce false-negative results depending not only on the time of the last ingestion of the drug by the mother but also on the length of time after birth when the specimen was collected [42]. COT but not NIC concentrations in mothers’ plasma, breast milk, and infants’ urine reflected the smoking habits during pregnancy [43]. However, in other studies this relationship was not corroborated, after studying 429 mothers and their newborns, measuring COT concentrations in neonatal urine and cord serum [42]. Recently, meconium became the specimen of choice for detecting drug exposure in neonates. Meconium can be collected between 1 and 5 days after birth, and its collection is easy and non-invasive. Drug concentrations in meconium are generally higher than in urine because of accumulation over several months of gestation. Recently, Gray TR et al. [56] demonstrated that there was a significant correlation between NIC and metabolites in meconium and a decrease in head circumference.

4.2. Biological Matrices for the Evaluation of Postnatal Exposure to Environmental Tobacco Smoke

Oral fluid is an interesting ETS marker for acute consumption that occurred in the hours previous to the collection, and is less invasive and more cost-effective than blood. Transfer of tobacco smoke constituents and their metabolites from blood to saliva occurs primarily by passive diffusion. Jarvis et al. [57] developed different methods for the quantification of COT in saliva. Using a cohort of 569 non-smoking school-children, they measured COT concentration in saliva. The study showed that
when neither parent smoked, the mean concentration was lower than that for either parent or the sum of the concentration for both the parents. Hair testing has been considered the “gold standard” to assess chronic ETS. Because COT accumulates in hair during hair growth, it is a unique measure of long-term, cumulative exposure to tobacco smoke. The major potential advantage of the hair test, when compared with saliva and serum measurements, is its ability to reflect long-term exposure (months) rather than short-term exposure (hours or days). It is estimated that hair grows at approximately 1 cm/month [65]. Therefore, hair can be analyzed in monthly, 1-cm segments, creating a “calendar” of NIC exposure [51]. Pichini et al. [66] measured NIC and its principal metabolite in 24 children aged 3–36 months attending a nursery school in the suburbs of Rome. For the first time, in the paediatric population, NIC measurement in hair was used to categorize different statuses of chronic exposure to ETS. Al-Delaimy et al. [67,68] measured NIC hair levels in 117 children and evaluated the effect of avoidance strategies such as smoking outside the household. Levels of NIC in hair of children reportedly exposed to smokers were higher than levels of unexposed children. A disadvantage of hair analysis is the need to use analytical methods based on chromatography techniques coupled with MS methods that require qualified personnel. Teeth demonstrated the potential of this biological matrix as an important deposit of exogenous substances, which can accumulate both in the pulp and in the calcified tissues. Garcia-Algar et al. [58] analyzed NIC and COT in deciduous teeth from children of both non-smoking and smoking parents. The results support NIC analysis in teeth as a promising non-invasive tool for monitoring and categorizing cumulative exposure to ETS from fetal life [59].

5. Policies to Diminish the ETS during Pregnancy and in the Entire Childhood

Smoke-free policies have been expanded worldwide since the WHO encouraged countries to follow Article 8 of the Framework Convention on Tobacco Control (FCTC) [2] to protect people from SHS. Legislation has been widely implemented in indoor public places, workplaces, and public transportation [69]. Several countries have implemented legislations requiring all enclosed workplace and public places to be free of SHS [70]. Ireland was the first country with comprehensive smoke-free legislation implemented in 2004. Since then, countries like Norway, New Zealand, Italy, Spain, Uruguay, England and many provinces or states in Canada, the USA or Australia [64,71] followed. This law includes health recommendations against smoking and recommendations for regulation of tobacco smoking in public places with wide exemptions in bars, restaurants and night clubs.

Data from different investigations carried out worldwide on the effects of smoking bans on ETS demonstrate clearly that SHS has decreased after the implementation of smoke-free legislation although in some cases (hospitality venues) high SHS levels have been found [72]. Interventions to reduce exposure to SHS have been found to reduce the incidence of cardiovascular diseases [73–76] but only few studies have examined the effect on pregnancy outcomes [15,77,78].

The scientific results showed a decreasing trend of exposure to SHS and an increase in the number of individuals not-exposed to SHS [79], including prenatal non-exposure to SHS [64,76,78,80]. Results from a cohort study performed in our hospital located in Barcelona city (Spain) examined the effect of Spanish legislation in three populations (1998–2006) of newborns recruited at different times during the implementation of the law [78]. These results demonstrate a decrease in SHS evidenced by a higher percentage of samples with cord blood COT < 1 ng/mL. The mean cord blood COT levels in the newborns from all the study groups were: 3.21 ng/mL in 1996–1998, 0.80 ng/mL
in 2002–2004 and 0.44 ng/mL in 2008. The percentage of no prenatal SHS exposure (cord blood COT 0.2–1 ng/mL) showed an increase compared to the previous groups (1996–1998 and 2002–2004) while the percentages of both: low (1.1–14 ng/mL) and very high (>100 ng/mL) prenatal SHS exposure showed a decrease in the number of babies recruited after the implementation of the smoke-free law. The change could be explained as a combination of several factors: negative messages in communication media and the public awareness derived from them; the implementation in 2005 of Spanish smoke-free legislation; and the increase in the tobacco price for the fiscal modification. Another fact that can explain this decrease could be the implementation of programs to help smoking pregnant women to quit (program “EmbaràsSense Fum”) in Catalonia. These programs included specific training and free NIC replacement treatment for pregnant smoking women throughout pregnancy [81].

In other countries, such as Italy, the joint action of legislation and prevention through campaigns against smoking has turned Italy into one of the countries with a lower percentage of non-smoking pregnant women exposed to ETS and the lowest percentage of women smoking during pregnancy, as shown in an urban area. In Italy, Franchini M et al., using questionnaires and cord blood COT, demonstrated that 13.5% of newborns were exposed to ETS and 7.7% were exposed to active maternal smoke [64]. In England, Sims M et al. using questionnaires and saliva COT, obtained similar results [76,82].

Despite that, few scientific articles have analyzed the effect of this decrease in the SHS in the paediatric population. McKay DF et al. [83] determined the impact of the Scottish’s legislation on preterm delivery. His data shows a reduction in the risk of preterm delivery (−11.72%, 95% CI −15.87, −7.35, p<0.001) and a reduction in the prevalence of current smoking which fell from 25.4% before legislation to 18.8% after legislation but this evaluation was not performed using the appropriate markers to assess SHS exposure (e.g., airborne NIC and COT in saliva). These results have now been confirmed in several follow-up studies [77,84,85].

6. Conclusions

Tobacco smoke, active or passive, is the most prevalent substance used during pregnancy worldwide. It is well established that active maternal smoking (and ETS) during pregnancy impairs foetal growth and shortens gestation producing deleterious birth outcomes. Since 2005, different countries, including Spain, have approved different smoke-free laws that ban smoking in all public places and workplaces including restaurants and pubs in order to protect people from high levels of exposure. Moreover, the development of new techniques to determine NIC and its metabolites in non-conventional matrices such as saliva, cord blood or hair has been a tremendous step in assessing the occult prevalence of ETS in newborns and children. Using objective biomarkers, different studies have demonstrated a decrease in the level of exposure after the implementation of smoke-free laws. Due to the decrease in the prevalence of SHS exposure, there are a few publications which highlighted the normalization of birth weight and preterm birth incidence but more studies are needed to confirm these preliminary observations.
Acknowledgments

The authors want to thank Julia Klein for excellent language editing service. This study was supported by Grants from Fondo de Investigaciones Sanitarias (FIS) (PI10/02593/PI13/01135) and Red de Salud Materno-Infantil y del Desarrollo (SAMID) (RD12/0026/0003), Instituto de Salud Carlos III (Spain), intramural funding of the Neuroscience Program at IMIM (Institut Hospital del Mar d’Investigacions Mèdiques) and partially supported by Generalitat de Catalunya (Spain) AGAUR (2009SGR1388).

Author Contributions

Xavier Joya reviewed the literature and the final manuscript, and was the main contributor in writing the manuscript. Full-texts of studies judged by title and abstract to be relevant were read and independently evaluated by the authors (Xavier Joya, Cristina Manzano, Airam-Tenesor Alvárez, Maria Mercadal, Francesc Torres, Judith Salat-Batlle and Oscar García-Algar). Xavier Joya, Judith Salat-Batlle and Oscar García-Algar, were the responsible for coordination of data and contributed in writing the manuscript. Oscar García-Algar was the expert responsible for final data analysis and contributed in writing the manuscript. All authors read and approved the final manuscript.

Conflicts of Interest

The authors declare no conflict of interest.

References

1. Schramm, S.; Carre, V.; Scheffler, J.L.; Aubriet, F. Analysis of mainstream and sidestream cigarette smoke particulate matter by laser desorption mass spectrometry. Anal. Chem. 2011, 83, 133–142.
2. WHO Framework Convention on Tobacco Control; World Health Organization (WHO): Geneva, Switzerland, 2003.
3. Murray, R.L.; Britton, J.; Leonard-Bee, J. Second hand smoke exposure and the risk of invasive meningococcal disease in children: Systematic review and meta-analysis. BMC Public Health 2012, 12, doi:10.1186/1471-2458-12-1062.
4. Burke, H.; Leonard-Bee, J.; Hashim, A.; Pine-Abata, H.; Chen, Y.; Cook, D.G.; Britton, J.R.; McKeever, T.M. Prenatal and passive smoke exposure and incidence of asthma and wheeze: Systematic review and meta-analysis. Pediatrics 2012, 129, 735–744.
5. Leonard-Bee, J.; Smyth, A.; Britton, J.; Coleman, T. Environmental tobacco smoke and fetal health: Systematic review and meta-analysis. Arch. Dis. Child. Fetal Neonatal. 2008, 93, 351–361.
6. DiFranza, J.R.; Aligne, C.A.; Weitzman, M. Prenatal and postnatal environmental tobacco smoke exposure and children’s health. Pediatrics 2004, 113, 1007–1015.
7. Flenady, V.; Koopmans, L.; Middleton, P.; Froen, J.F.; Smith, G.C.; Gibbons, K.; Coory, M.; Gordon, A.; Ellwood, D.; McIntyre, H.D.; et al. Major risk factors for stillbirth in high-income countries: A systematic review and meta-analysis. Lancet 2011, 377, 1331–1340.
8. Salmasi, G.; Grady, R.; Jones, J.; McDonald, S.D. Environmental tobacco smoke exposure and perinatal outcomes: A systematic review and meta-analyses. *Acta Obstet. Gynecol. Scand.* 2010, 89, 423–441.

9. Hackshaw, A.; Rodeck, C.; Boniface, S. Maternal smoking in pregnancy and birth defects: A systematic review based on 173,687 malformed cases and 11.7 million controls. *Hum. Reprod. Update* 2011, 17, 589–604.

10. Oberg, M.; Jaakkola, M.S.; Woodward, A.; Peruga, A.; Pruss-Ustun, A. Worldwide burden of disease from exposure to second-hand smoke: A retrospective analysis of data from 192 countries. *Lancet* 2011, 377, 139–146.

11. Nieuwenhuijsen, M.J.; Dadvand, P.; Grellier, J.; Martinez, D.; Vrijheid, M. Environmental risk factors of pregnancy outcomes: A summary of recent meta-analyses of epidemiological studies. *Environ. Health* 2013, 12, doi:10.1186/1476-069X-12-6.

12. Windham, G.C.; Hopkins, B.; Fenster, L.; Swan, S.H. Prenatal active or passive tobacco smoke exposure and the risk of preterm delivery or low birth weight. *Epidemiology* 2000, 11, 427–433.

13. Fantuzzi, G.; Aggazzotti, G.; Righi, E.; Facchinetti, F.; Bertucci, E.; Kanitz, S.; Barbone, F.; Sansebastiano, G.; Battaglia, M.A.; Leoni, V.; *et al*. Preterm delivery and exposure to active and passive smoking during pregnancy: A case-control study from Italy. *Paediatr. Perinat. Epidemiol.* 2007, 21, 194–200.

14. Ahluwalia, I.B.; Grummer-Strawn, L.; Scanlon, K.S. Exposure to environmental tobacco smoke and birth outcome: Increased effects on pregnant women aged 30 years or older. *Amer. J. Epidemiol.* 1997, 146, 42–47.

15. El-Mohandes, A.A.; Kiely, M.; Blake, S.M.; Gantz, M.G.; El-Khorazaty, M.N. An intervention to reduce environmental tobacco smoke exposure improves pregnancy outcomes. *Pediatrics* 2010, 125, 721–728.

16. Jaakkola, J.J.; Jaakkola, N.; Zahlsen, K. Fetal growth and length of gestation in relation to prenatal exposure to environmental tobacco smoke assessed by hair nicotine concentration. *Environ. Health Perspect.* 2001, 109, 557–561.

17. Collet, M.; Beillard, C. Consequences of smoking on fetal development and risk of intra-uterine growth retardation or in utero fetal death. *J. Gynecol. Obstet. Biol. Reprod.* 2005, 34, S135–S145.

18. Okah, F.A.; Cai, J.; Dew, P.C.; Hoff, G.L. Are fewer women smoking during pregnancy? *Am. J. Health Behav.* 2005, 29, 456–461.

19. Adamek, R.; Florek, E.; Piekoszewski, W.; Anholcer, A.; Kaczmarek, E. Effect of exposure to tobacco smoke and selected socioeconomic factors in occurrence of low birth weight. *Przegl. Lek.* 2005, 62, 965–969.

20. Windham, G.C.; Eaton, A.; Hopkins, B. Evidence for an association between environmental tobacco smoke exposure and birthweight: A meta-analysis and new data. *Paediatr. Perinat. Epidemiol.* 1999, 13, 35–57.

21. Khoury, M.J.; Gomez-Farias, M.; Mulinare, J. Does maternal cigarette smoking during pregnancy cause cleft lip and palate in offspring? *Amer. J. Dis. Child.* 1989, 143, 333–337.
22. Apostol, G.G.; Jacobs, D.R., Jr.; Tsai, A.W.; Crow, R.S.; Williams, O.D.; Townsend, M.C.; Beckett, W.S. Early life factors contribute to the decrease in lung function between ages 18 and 40: The Coronary Artery Risk Development in Young Adults study. Amer. J. Respir. Crit. Care Med. 2002, 166, 166–172.

23. Julvez, J.; Ribas-Fito, N.; Torrent, M.; Forns, M.; Garcia-Esteban, R.; Sunyer, J. Maternal smoking habits and cognitive development of children at age 4 years in a population-based birth cohort. Int. J. Epidemiol. 2007, 36, 825–832.

24. Ekblad, M.; Gissler, M.; Lehtonen, L.; Korkeila, J. Prenatal smoking exposure and the risk of psychiatric morbidity into young adulthood. Arch. Gen. Psychiat. 2010, 67, 841–849.

25. Cook, D.G.; Strachan, D.P. Parental smoking, bronchial reactivity and peak flow variability in children. Thorax 1998, 53, 295–301.

26. Martinez, F.D.; Antognoni, G.; Macri, F.; Bonci, E.; Midulla, F.; de Castro, G.; Ronchetti, R. Parental smoking enhances bronchial responsiveness in nine-year-old children. Amer. Rev. Resp. Dis. 1988, 138, 518–523.

27. Martinez, F.D.; Wright, A.L.; Taussig, L.M.; Holberg, C.J.; Halonen, M.; Morgan, W.J. Asthma and wheezing in the first six years of life. The Group Health Medical Associates. N. Engl. J. Med. 1995, 332, 133–138.

28. Hanrahan, J.P.; Tager, I.B.; Segal, M.R.; Tosteson, T.D.; Castile, R.G.; van Vunakis, H.; Weiss, S.T.; Speizer, F.E. The effect of maternal smoking during pregnancy on early infant lung function. Amer. Rev. Resp. Dis. 1992, 145, 1129–1135.

29. Young, S.; le Souef, P.N.; Geelhoed, G.C.; Stick, S.M.; Turner, K.J.; Landau, L.I. The influence of a family history of asthma and parental smoking on airway responsiveness in early infancy. N. Engl. J. Med. 1991, 324, 1168–1173.

30. Johansson, A.; Ludvigsson, J.; Hermansson, G. Adverse health effects related to tobacco smoke exposure in a cohort of three-year olds. Acta Paediat. 2008, 97, 354–357.

31. Puig, C.; Friguls, B.; Gomez, M.; Garcia-Algar, O.; Sunyer, J.; Vall, O. Relationship between lower respiratory tract infections in the first year of life and the development of asthma and wheezing in children. Arch. Bronconeumol. 2010, 46, 514–521.

32. Strachan, D.P.; Cook, D.G. Health effects of passive smoking. 1. Parental smoking and lower respiratory illness in infancy and early childhood. Thorax 1997, 52, 905–914.

33. Friguls, B.; Garcia-Algar, O.; Puig, C.; Figueroa, C.; Sunyer, J.; Vall, O. Perinatal exposure to tobacco and respiratory and allergy symptoms in first years of life. Arch. Bronconeumol. 2009, 45, 585–590.

34. Puig, C.; Sunyer, J.; Garcia-Algar, O.; Munoz, L.; Pacifi, R.; Pichini, S.; Vall, O. Incidence and risk factors of lower respiratory tract illnesses during infancy in a Mediterranean birth cohort. Acta Paediat. 2008, 97, 1406–1411.

35. Yuan, H.; Wong, L.S.; Bhattacharya, M.; Ma, C.; Zafarani, M.; Yao, M.; Schneider, M.; Pitas, R.E.; Martins-Green, M. The effects of second-hand smoke on biological processes important in atherogenesis. BMC Cardiovasc. Disord. 2007, 7, doi: 10.1186/1471-2261-7-1

36. Moskowitz, W.B.; Schwartz, P.F.; Schieken, R.M. Childhood passive smoking, race, and coronary artery disease risk: The MCV Twin Study. Medical College of Virginia. Arch. Pediatr. Adolesc. Med. 1999, 153, 446–453.
37. Simonetti, G.D.; Schwertz, R.; Klett, M.; Hoffmann, G.F.; Schaefer, F.; Wuhl, E. Determinants of blood pressure in preschool children: The role of parental smoking. Circulation 2011, 123, 292–298.

38. Shiono, P.H.; Klebanoff, M.A.; Nugent, R.P.; Cotch, M.F.; Wilkins, D.G.; Rollins, D.E.; Carey, J.C.; Behrman, R.E. The impact of cocaine and marijuana use on low birth weight and preterm birth: A multicenter study. Amer. J. Obstet. Gynecol. 1995, 172, 19–27.

39. Lambers, D.S.; Clark, K.E. The maternal and fetal physiologic effects of nicotine. Semin. Perinatol. 1996, 20, 115–126.

40. Bearer, C.; Emerson, R.K.; O’Riordan, M.A.; Roitman, E.; Shackleton, C. Maternal tobacco smoke exposure and persistent pulmonary hypertension of the newborn. Environ. Health Perspect. 1997, 105, 202–206.

41. Villalbi, J.R.; Vives, R.; Nebot, M.; Diez, E.; Ballestin, M. Smoking and school children: Context, opinions and behavior. Med. Clin. 1998, 110, 579–581.

42. Pichini, S.; Basagana, X.B.; Pacifici, R.; Garcia, O.; Puig, C.; Vall, O.; Harris, J.; Zuccaro, P.; Segura, J.; Sunyer, J. Cord serum cotinine as a biomarker of fetal exposure to cigarette smoke at the end of pregnancy. Environ. Health Perspect. 2000, 108, 1079–1083.

43. Aranda Regules, J.M.; Mateos Vilchez, P.; Gonzalez Villalba, A.; Sanchez, F.; Luna del Castillo, J.D. Validity of smoking measurements during pregnancy: Specificity, sensitivity and cut-off points. Rev. Esp. Salud Publica 2008, 82, 535–545.

44. Friguls, B.; Joya, X.; Garcia-Serra, J.; Gomez-Culebras, M.; Pichini, S.; Martinez, S.; Vall, O.; Garcia-Algar, O. Assessment of exposure to drugs of abuse during pregnancy by hair analysis in a Mediterranean island. Addiction 2012, 107, 1471–1479.

45. Puig, C.; Garcia-Algar, O.; Monleon, T.; Pacifici, R.; Zuccaro, P.; Sunyer, J.; Figueroa, C.; Pichini, S.; Vall, O. A longitudinal study of environmental tobacco smoke exposure in children: Parental self reports versus age dependent biomarkers. BMC Public Health 2008, 8, doi: 10.1186/1471-2458-8-47.

46. Klebanoff, M.A.; Levine, R.J.; Clemens, J.D.; DerSimonian, R.; Wilkins, D.G. Serum cotinine concentration and self-reported smoking during pregnancy. Amer. J. Epidemiol. 1998, 148, 259–262.

47. Wu, F.Y.; Chiu, H.T.; Wu, H.D.; Lin, C.J.; Lai, J.S.; Kuo, H.W. Comparison of urinary and plasma cotinine levels during the three trimesters of pregnancy. Paediatr. Perinat. Epidemiol. 2008, 22, 296–301.

48. Llaquet, H.; Pichini, S.; Joya, X.; Papaseit, E.; Vall, O.; Klein, J.; Garcia-Algar, O. Biological matrices for the evaluation of exposure to environmental tobacco smoke during prenatal life and childhood. Anal. Bioanal. Chem. 2010, 396, 379–399.

49. Martinez-Sanchez, J.M.; Fernandez, E.; Fu, M.; Pascual, J.A.; Ariza, C.; Agudo, A.; Borras, J.M.; Schiaffino, A.; Moncada, A.; Jane, M.; et al. Assessment of exposure to secondhand smoke by questionnaire and salivary cotinine in the general population of Barcelona, Spain (2004–2005). Prev. Med. 2009, 48, 218–223.

50. Dhar, P. Measuring tobacco smoke exposure: Quantifying nicotine/cotinine concentration in biological samples by colorimetry, chromatography and immunoassay methods. J. Pharm. Biomed. Anal. 2004, 35, 155–168.
51. Matt, G.E.; Quintana, P.J.; Hovell, M.F.; Bernert, J.T.; Song, S.; Novianti, N.; Juarez, T.; Floro, J.; Gehrman, C.; Garcia, M.; et al. Households contaminated by environmental tobacco smoke: Sources of infant exposures. *Tob. Control*. **2004**, *13*, 29–37.

52. Chazeron, I.; Daval, S.; Ughetto, S.; Richard, D.; Nicolay, A.; Lemery, D.; Llorca, P.M.; Coudore, F. GC-MS determined cotinine in an epidemiological study on smoking status at delivery. *Pulm. Pharmacol. Ther.* **2008**, *21*, 485–488.

53. Mansi, G.; Raimondi, F.; Pichini, S.; Capasso, L.; Sarno, M.; Zuccaro, P.; Pacifici, R.; Garcia-Algar, O.; Romano, A.; Paludetto, R. Neonatal urinary cotinine correlates with behavioral alterations in newborns prenatally exposed to tobacco smoke. *Pediatr. Res.* **2007**, *61*, 257–261.

54. Kohler, E.; Bretschneider, D.; Rabsilber, A.; Weise, W.; Jorch, G. Assessment of prenatal smoke exposure by determining nicotine and its metabolites in maternal and neonatal urine. *Hum. Exp. Toxicol.* **2001**, *20*, 1–7.

55. Jauniaux, E.; Gulbis, B.; Acharya, G.; Thiry, P.; Rodeck, C. Maternal tobacco exposure and cotinine levels in fetal fluids in the first half of pregnancy. *Obstet. Gynecol.* **1999**, *93*, 25–29.

56. Gray, T.R.; Magri, R.; Shakleya, D.M.; Huestis, M.A. Meconium nicotine and metabolites by liquid chromatography-tandem mass spectrometry: Differentiation of passive and nonexposure and correlation with neonatal outcome measures. *Clin. Chem.* **2008**, *54*, 2018–2027.

57. Jarvis, M.J.; Russell, M.A.; Feyerabend, C.; Eiser, J.R.; Morgan, M.; Gammage, P.; Gray, E.M. Passive exposure to tobacco smoke: Saliva cotinine concentrations in a representative population sample of non-smoking schoolchildren. *Brit. Med. J.* **1985**, *291*, 927–929.

58. Garcia-Algar, O.; Vall, O.; Segura, J.; Pascual, J.A.; Diaz, D.; Mutnoz, L.; Zuccaro, P.; Pacifici, R.; Pichini, S. Nicotine concentrations in deciduous teeth and cumulative exposure to tobacco smoke during childhood. *JAMA* **2003**, *290*, 196–197.

59. Marchei, E.; Joya, X.; Garcia-Algar, O.; Vall, O.; Pacifici, R.; Pichini, S. Ultrasensitive detection of nicotine and cotinine in teeth by high-performance liquid chromatography/tandem mass spectrometry. *Rapid Commun. Mass Spectrom.* **2008**, *22*, 2609–2612.

60. Benowitz, N.L.; Jacob, P., 3rd, Nicotine and cotinine elimination pharmacokinetics in smokers and nonsmokers. *Clin. Pharmacol. Ther.* **1993**, *53*, 316–323.

61. Tricker, A.R. Nicotine metabolism, human drug metabolism polymorphisms, and smoking behaviour. *Toxicology* **2003**, *183*, 151–173.

62. Perez-Stable, E.J.; Benowitz, N.L.; Marin, G. Is serum cotinine a better measure of cigarette smoking than self-report? *Prev. Med.* **1995**, *24*, 171–179.

63. Boffetta, P.; Clark, S.; Shen, M.; Gislafoss, R.; Peto, R.; Andersen, A. Serum cotinine level as predictor of lung cancer risk. *Cancer Epidem. Biomarker. Prev.* **2006**, *15*, 1184–1188.

64. Franchini, M.; Caruso, C.; Perico, A.; Pacifici, R.; Monleon, T.; Garcia-Algar, O.; Rossi, S.; Pichini, S. Assessment of foetal exposure to cigarette smoke after recent implementations of smoke-free policy in Italy. *Acta Paediatr.* **2008**, *97*, 546–550.

65. Nakahara, Y. Hair analysis for abused and therapeutic drugs. *J. Chromatogr. B-Bio. Med. Appl.* **1999**, *733*, 161–180.

66. Pichini, S.; Altieri, I.; Pellegrini, M.; Pacifici, R.; Zuccaro, P. Hair analysis for nicotine and cotinine: Evaluation of extraction procedures, hair treatments, and development of reference material. *Forensic Sci. Int.* **1997**, *84*, 243–252.
67. Al-Delaimy, W.K.; Crane, J.; Woodward, A. Questionnaire and hair measurement of exposure to tobacco smoke. *J. Expos. Anal. Environ. Epidem.* **2000**, *10*, 378–384.

68. Al-Delaimy, W.K.; Crane, J.; Woodward, A. Passive smoking in children: Effect of avoidance strategies, at home as measured by hair nicotine levels. *Arch. Environ. Health* **2001**, *56*, 117–122.

69. *Report on the Global Tobacco Epidemic, 2009: Implementing Smoke-Free Environments*; WHO: Geneva, Switzerland, 2009.

70. Fernandez, E.; Fu, M.; Pascual, J.A.; Lopez, M.J.; Perez-Rios, M.; Schiaffino, A.; Martinez-Sanchez, J.M.; Ariza, C.; Salto, E.; Nebot, M. Impact of the Spanish smoking law on exposure to second-hand smoke and respiratory health in hospitality workers: A cohort study. *PLoS One* **2009**, *4*, doi:10.1371/journal.pone.0004244.

71. Akhtar, P.C.; Currie, D.B.; Currie, C.E.; Haw, S.J. Changes in child exposure to environmental tobacco smoke (CHETS) study after implementation of smoke-free legislation in Scotland: National cross sectional survey. *BMJ* **2007**, *335*, 335, doi:10.1136/bmj.39311.550197.AE.

72. Sureda, X.; Fernandez, E.; Lopez, M.J.; Nebot, M. Secondhand tobacco smoke exposure in open and semi-open settings: A systematic review. *Environ. Health Perspect.* **2013**, *121*, 766–773.

73. Stallings-Smith, S.; Zeka, A.; Goodman, P.; Kabir, Z.; Clancy, L. Reductions in cardiovascular, cerebrovascular, and respiratory mortality following the national irish smoking ban: Interrupted time-series analysis. *PLoS One* **2013**, *8*, doi:10.1371/journal.pone.0062063.

74. Barone-Adesi, F.; Vizzini, L.; Merletti, F.; Richiardi, L. Short-term effects of Italian smoking regulation on rates of hospital admission for acute myocardial infarction. *Eur. Heart J.* **2006**, *27*, 2468–2472.

75. Meyers, D.G.; Neuberger, J.S.; He, J. Cardiovascular effect of bans on smoking in public places: A systematic review and meta-analysis. *J. Amer. Coll. Cardiol.* **2009**, *54*, 1249–1255.

76. Sims, M.; Maxwell, R.; Bauld, L.; Gilmore, A. Short term impact of smoke-free legislation in England: Retrospective analysis of hospital admissions for myocardial infarction. *BMJ* **2010**, *340*, doi:10.1136/bmj.c2161.

77. Kabir, Z.; Clarke, V.; Conroy, R.; McNamee, E.; Daly, S.; Clancy, L. Low birthweight and preterm birth rates 1 year before and after the Irish workplace smoking ban. *BJOG* **2009**, *116*, 1782–1787.

78. Puig, C.; Vall, O.; Garcia-Algar, O.; Papaseit, E.; Pichini, S.; Salto, E.; Villalbi, J.R. Assessment of prenatal exposure to tobacco smoke by cotinine in cord blood for the evaluation of smoking control policies in Spain. *BMC Pregnancy Childbirth* **2012**, *12*, doi:10.1186/1471-2393-12-26.

79. Sureda, X.; Martinez-Sanchez, J.M.; Fu, M.; Perez-Ortuno, R.; Martinez, C.; Carabasa, E.; Lopez, M.J.; Salto, E.; Pascual, J.A.; Fernandez, E. Impact of the Spanish smoke-free legislation on adult, non-smoker exposure to secondhand smoke: Cross-sectional surveys before (2004) and after (2012) legislation. *PLoS One* **2014**, *9*, doi:10.1371/journal.pone.0089430.

80. Charrier, L.; Serafini, P.; Giordano, L.; Zotti, C.M. Smoking habits in Italian pregnant women: Any changes after the ban? *J. Public Health Policy* **2010**, *31*, 51–58.

81. Protocol del Programa “Embaràs Sense Fum”. Available online: http://www.20.gencat.cat/docs/canalsalut/Home%20Canal%20Salut/Professionals/Temes_de_salut/Tabaquisme/documents/prote_mbaras2007fum.pdf (accessed on 15 May 2014).
82. Sims, M.; Bauld, L.; Gilmore, A. England’s legislation on smoking in indoor public places and work-places: Impact on the most exposed children. *Addiction* **2012**, *107*, 2009–2016.

83. Mackay, D.F.; Nelson, S.M.; Haw, S.J.; Pell, J.P. Impact of Scotland’s smoke-free legislation on pregnancy complications: Retrospective cohort study. *PLoS Med.* **2012**, *9*, doi:10.1371/journal.pmed.1001175.

84. Cox, B.; Martens, E.; Nemery, B.; Vangronsveld, J.; Nawrot, T.S. Impact of a stepwise introduction of smoke-free legislation on the rate of preterm births: Analysis of routinely collected birth data. *BMJ* **2013**, *346*, doi:10.1136/bmj.f441.

85. Page, R.L., Jr.; Slejko, J.F.; Libby, A.M. A citywide smoking ban reduced maternal smoking and risk for preterm births: A Colorado natural experiment. *J. Womens Health* **2012**, *21*, 621–627.

© 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).